Horizon Scanning: FDA grants orphan drug status to lenvatinib for thyroid cancer

Source: BioSpace Area: News According to a review in Biospace, The U.S FDA has granted orphan drug designation to lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer. Lenvatinib is an investigational small molecule tyrosine kinase inhibitor being studied as an oral agent in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news